Conclusion
Early initiation of novel treatments (thrombolytics and neuroprotectants) in patients with acute ischaemic stroke is likely to improve the outcome for these patients. However, both of these types of treatment must be given as early as possible for optimal effect and safety. While the administration of thrombolytics requires a definitive diagnosis, it is hoped that in the future, it may be possible to treat patients with neuroprotective treatments before the patient arrives in hospital. In order for this to happen, emergency service personnel should be able to evaluate a stroke patient promptly, and be aware of the need to treat stroke as an emergency. Additionally, the general public needs to be educated to recognise the signs and symptoms of stroke and to react quickly to them by calling the emergency number.
1 1 Adams HJ, Brott T, Furlan A, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Following occlusion of a cerebral vessel, by thrombosis or embolism, blood flow to an area of the brain is reduced. The affected brain has a central area of infarction surrounded by an "ischaemic penumbra" of potentially salvageable tissue.3 The two areas are not clearly demarcated and the volume of potentially salvageable tissue is constantly declining according to the interaction between duration and severity of ischaemia.'
At a cellular level hypoperfusion reduces the supply of oxygen and glucose available for the aerobic production of ATP. Anaerobic metabolism provides inadequate levels of ATP to maintain cellular function which is further compromised by lactic acid generation. Membrane pump failure results and causes a wave of depolarisation. This in turn stimulates a massive release of glutamate and other excitatory neurotransmitters. The inability to remove these molecules from the synaptic cleft, another energy requiring process, causes the glutamate sensitive N-methyl-D-aspartate (NMDA) channels in the neuronal cell membrane to open and allow unrestricted influx of sodium and calcium. Sodium draws water with it causing neurones to swell, and the calcium influx activates proteolytic enzymes and lipases, which in turn cause generation of free radicals and prostaglandins. These changes, which lead to cellular death are summarised in fig 1. Ischaemic injury to vessels within the stroke territory causes increased vascular permeabil- Within these constraints the newer techniques of MRI and MR spectroscopy with diffusion weighted imaging allow differentiation between infarcted and ischaemic tissue." When these imaging modalities are more widely available they will permit patient selection for thrombolysis based on identification of potentially salvageable tissue rather than by application of a rigid time interval from symptom onset. The latter may exclude patients who could still benefit from treatment and includes, and exposes to the risk of haemorrhage, some patients with little salvageable tissue (see figs 2, 3, and 4).
Treatment options Potential treatments may be categorised by mechanism of action. Interventions such as thrombolytics and antithrombotics, which aim to improve blood supply to affected tissue, are distinguished from neuroprotective agents which aim to reduce the damage caused by ischaemia. An alternative classification differentiates simple, often inexpensive, interventions, which can be widely used after minimal investigation from treatments such as thrombolysis, which are expensive and can only be used on a relatively small group of patients after intensive investigation.
The first group may produce considerably smaller percentage improvements in outcome but their broad applicability may result in a greater overall benefit to populations. Recognition of these differences'2 and the impact they should have on trial design has been clearly defined. 13 Many potential treatments require prompt institution if they are to be helpful, and education of the public and the medical profession to expedite hospitalisation of patients with stroke will become more important. Management of patients by dedicated stroke teams in their own units is also of proved benefit. " No studies have investigated the importance of raising blood pressure in patients who are hypotensive at presentation. Theoretical considerations suggest that this should be expedited in order to improve cerebral perfusion pressure and this is the recommendation of the Stroke Council of the American Heart Association in their guidelines on stroke management. 15 Haemodilution Intentional haemodilution, which may be isovolaemic or hypervolaemic, is known to improve oxygen delivery to peripheral tissues and has been used since the 1 960s as a treatment for acute ischaemic stroke. As the packed cell volume (PCV) is reduced oxygen delivery increases to a peak but then falls as the loss of oxygen carrying capacity outweighs the reduction in blood viscosity. The peak lies at a PCV of 0.30-0.33 in normal peripheral tissues but there is evidence that in brain tissue the maximum may be as high as 0.40-0.45. Formal analysis of the 15 randomised controlled trials available has shown no reduction in early or late case fatality or functional outcome and this once popular treatment is no longer recommended.'8 However it should be noted that in these studies patients were treated up to 72 hours after onset of symptoms. There is some evidence from animal studies suggesting that haemodilution performed within three hours of cerebral occlusion can significantly alter infarct size.'9 Further studies are required in this area.
Corticosteroids
Cerebral oedema is a significant cause of death after stroke both directly by reduction of cerebral perfusion pressure and indirectly by inducing vasospasm. Cerebral oedema may be vasogenic (related to breakdown of the bloodbrain barrier as in tumours) or cytotoxic (related to cell membrane dysfunction as occurs in focal or generalised ischaemia). While corticosteroids have a proved role in the management of vasogenic oedema they are not of value in the predominantly cytotoxic oedema of acute stroke. Meta-analysis of available trials has shown that their use confers no benefit and that there is also possibly a higher fatality rate among patients receiving them.20
Antithrombotic and antiplatelet aggregating drugs These agents, which are extensively used in the prevention of ischaemic vascular events, have yet to have their role fully established in acute stroke. The rationale for their use is clearthey should help to maintain or improve perfusion to the brain by halting the propagation of thrombus or preventing recurrent thromboembolism. They may also reduce mortality and morbidity by preventing common complications of stroke such as deep vein thrombosis and pulmonary embolism.
Heparin has been used widely in stroke management over the past 50 years. However in the 1994 guidelines on the management of acute ischaemic stroke issued by the American Heart Association'5 the available data regarding its efficacy and safety were considered sufficiently unclear that no recommendation could be made about its use. Publication of the results of the International Stroke Trial in early 1997 has added clarification.2' A total of 19 435 patients with ischaemic stroke were allocated to receive within 48 hours of symptom onset either subcutaneous heparin (at a dose of 5000 or 12 500 IU) or placebo. The patients were also allocated, in a factorial design, to either receive aspirin or not. The study showed no overall benefit at six months for patients receiving heparin and demonstrated a significantly higher incidence of major extracranial bleeds, more haemorrhagic strokes, and more deaths or non-fatal strokes within 14 days for those patients allocated to the higher dose of heparin. The investigators concluded that if heparin were to be used in clinical practice the lower trial dose of 5000 IU twice a day should not be exceeded. In this subgroup there was a small but significant decrease of 1.2% in the incidence of early death or recurrent stroke without a significant increase of serious extracranial bleeds. This has prompted a recommendation for further studies. 22 Data relating to the efficacy of aspirin were analysed alone and, as previously planned, summated with the results of the Chinese Acute Stroke Trial.23 In this investigation 21 106 patients with suspected acute ischaemic stroke received within 48 hours of symptom onset either aspirin in a dose of 160 mg/day or placebo, continued for up to four weeks. Overall there was a small, but significant benefit to treatment with 13 per 1000 fewer dead or dependent in the first weeks and months of follow up.
Low molecular weight (LMW) heparins and heparinoids, both experimentally and clinically, are associated with a lower risk of bleeding than unfractionated heparin. Extensive investigations in prophylaxis of deep vein thrombosis shows them to be more effective and safer than heparin, aspirin, and anticoagulants.
The LMW heparin Nadroparin was used in two doses in the randomised, placebo controlled Hong Kong study.24 At six months unfavourable outcomes were reduced from 65% in a placebo group to 52% in a low dose treatment group and 45% in those patients receiving a higher dose of Nadroparin. Further trials are underway as they are for the LMW heparinoid Org 10172 which has shown encouraging results in pilot studies.25 Thrombolysis A variety of thrombolytic agents have been studied including streptokinase, urokinase, and t-PA using intravenous and intra-arterial routes for administration. Common to all trials is the frustration of finding the benefits of reperfusion partially or totally negated by the increased risk of intracranial haemorrhage.
The high levels of technical involvement associated with the intra-arterial route are responsible for the small number of studies of While many of the non-competitive NMDA antagonists used have shown substantial benefit in terms of reducing infarct size in experimental models, they have been unsuitable for clinical use because of their side effects. They block the NMDA receptor in a fashion similar to phencyclidine (angel dust) and can cause paranoia, hallucinations, agitation, or a decrease in conscious level.32 One of these agents, Aptiganel, has relatively fewer side effects and after encouraging results in a phase 11 study is currently under further investigation.33 A competitive blocker of the glycine regulatory site on the NMDA receptor, ACEA-1201, has also shown significant benefit in early trials and appears to be free of significant unwanted effects. 34 Of the agents working distant to the NMDA receptor lubeluzole is perhaps the most promising. Its mechanism of action involves both inhibiting the increase in extracellular glutamate concentrations and also inhibiting the nitric oxide synthetase pathway, which by production of intracellular nitric oxide contributes to ischaemic induced neuronal death. It has been evaluated in a clinical trial involving 232 patients.35 Patients receiving a low dose of lubeluzole showed a very significant improvement in 28 day mortality compared with placebo and functional outcome also appeared to be improved in survivors. However these benefits were not apparent in a higher dose group in which there was a significantly greater 28 day mortality compared with the placebo group. A larger trial of this drug is currently underway.
Conclusion
It is clear that the active management of stroke is an emerging discipline with many potential I11 group.bmj.com on May 29, 2017 -Published by http://emj.bmj.com/ Downloaded from therapies still at an experimental stage. Rigorous design and conduct of trials of these agents can play a significant part in allowing those treatments of proved efficacy to reach clinical practice quickly.
Although thrombolysis has only been shown to be of benefit when started soon after symptom onset, the possibility of giving a neuroprotectant drug early, perhaps in the pre-hospital setting, which will prolong the viability of the ischaemic neurones until more definitive treatment can be given is one which considerably broadens their applicability.
Emergency physicians have a pivotal role in expediting the imaging and treatment of acute stroke patients. Liaison with local colleagues to formulate policies on management is essential. As clear treatment guidelines become available it is increasingly obvious that the necessity for urgent intervention will make the role of the emergency department a crucial one if outcomes are to be improved.
